The OLO trial evaluates the effectiveness of Saint technology for the treatment of major depressive disorder (MDD). The platform delivers individualized, rapid-acting, non-invasive neurostimulation. Saint treats adults who fail to achieve satisfactory improvement from prior antidepressant medications in the current episode.
FDA cleared Saint for treating MDD in September 2022.
Saint combines advanced imaging technologies and personalized targeting and novel stimulation patterns. It uses structural and functional MRI to inform a proprietary algorithm. The algorithm identifies the optimal anatomic target for focused neurostimulation in people with MDD.
“We are very pleased to announce the start of the OLO clinical trial with Saint therapy for people with MDD who are ineffectively tre…